Skip to Content

Cotellic Dosage

Generic name: COBIMETINIB FUMARATE 20mg
Dosage form: tablet, film coated

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Patient Selection

Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of treatment with COTELLIC with vemurafenib. Information on FDA-approved tests for the detection of BRAF V600 mutations in melanoma is available at: http://www.fda.gov/CompanionDiagnostics.

Recommended Dose

The recommended dosage regimen of COTELLIC is 60 mg (three 20 mg tablets) orally taken once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity [see Clinical Studies (14)].

Take COTELLIC with or without food [see Clinical Pharmacology (12.3)].

If a dose of COTELLIC is missed or if vomiting occurs when the dose is taken, resume dosing with the next scheduled dose.

Dose Modifications

Concurrent CYP3A Inhibitors

Do not take strong or moderate CYP3A inhibitors while taking COTELLIC.

If concurrent short term (14 days or less) use of moderate CYP3A inhibitors is unavoidable for patients who are taking COTELLIC 60 mg, reduce COTELLIC dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume previous dose of COTELLIC 60 mg [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

Use an alternative to a strong or moderate CYP3A inhibitor in patients who are taking a reduced dose of COTELLIC (40 or 20 mg daily) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

Adverse Reactions

Review the Full Prescribing Information for vemurafenib for recommended dose modifications.

Table 1. Recommended Dose Reductions for COTELLIC
First Dose Reduction 40 mg orally once daily
Second Dose Reduction 20 mg orally once daily
Subsequent Modification Permanently discontinue COTELLIC if unable to tolerate 20 mg orally once daily
Table 2. Recommended Dose Modifications for COTELLIC for Adverse Reactions
Severity of Adverse Reaction* Dose Modification for COTELLIC
*
National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0)
New Primary Malignancies (cutaneous and non-cutaneous) No dose modification is required.
Hemorrhage
Grade 3 Withhold COTELLIC for up to 4 weeks.
  • If improved to Grade 0 or 1, resume at the next lower dose level.
  • If not improved within 4 weeks, permanently discontinue.
Grade 4 Permanently discontinue.
Cardiomyopathy
Asymptomatic, absolute decrease in LVEF from baseline of greater than 10% and less than institutional lower limit of normal (LLN) Withhold COTELLIC for 2 weeks; repeat LVEF.

Resume at next lower dose if all of the following are present
  • LVEF is at or above LLN and
  • Absolute decrease from baseline LVEF is 10% or less.

Permanently discontinue if any of the following are present

  • LVEF is less than LLN or
  • Absolute decrease from baseline LVEF is more than 10%.
Symptomatic LVEF decrease from baseline Withhold COTELLIC for up to 4 weeks, repeat LVEF.

Resume at next lower dose if all of the following are present:
  • Symptoms resolve and
  • LVEF is at or above LLN and
  • Absolute decrease from baseline LVEF is 10% or less.

Permanently discontinue if any of the following are present

  • Symptoms persist, or
  • LVEF is less than LLN, or
  • Absolute decrease from baseline LVEF is more than 10%.
Dermatologic Reactions
Grade 2 (intolerable), Grade 3 or 4 Withhold or reduce dose.
Serous Retinopathy or Retinal Vein Occlusion
Serous retinopathy Withhold COTELLIC for up to 4 weeks.
  • If signs and symptoms improve, resume at the next lower dose level.
  • If not improved or symptoms recur at the lower dose within 4 weeks, permanently discontinue.
Retinal vein occlusion Permanently discontinue COTELLIC.
Liver Laboratory Abnormalities and Hepatotoxicity
First occurrence Grade 4 Withhold COTELLIC for up to 4 weeks.
  • If improved to Grade 0 or 1, then resume at the next lower dose level.
  • If not improved to Grade 0 or 1 within 4 weeks, permanently discontinue.
Recurrent Grade 4 Permanently discontinue COTELLIC.
Rhabdomyolysis and Creatine Phosphokinase (CPK) elevations
  • Grade 4 CPK elevation
  • Any CPK elevation and myalgia
Withhold COTELLIC for up to 4 weeks.
  • If improved to Grade 3 or lower, resume at the next lower dose level.
  • If not improved within 4 weeks, permanently discontinue.
Photosensitivity
Grade 2 (intolerable), Grade 3 or Grade 4 Withhold COTELLIC for up to 4 weeks.
  • If improved to Grade 0 or 1, resume at the next lower dose level.
  • If not improved within 4 weeks, permanently discontinue.
Other
  • Grade 2 (intolerable) adverse reactions
  • Any Grade 3 adverse reactions
Withhold COTELLIC for up to 4 weeks.
  • If improved to Grade 0 or 1, resume at the next lower dose level.
  • If not improved within 4 weeks, permanently discontinue.
First occurrence of any Grade 4 adverse reaction
  • Withhold COTELLIC until adverse reaction improves to Grade 0 or 1. Then resume at the next lower dose level, OR
  • Permanently discontinue.
Recurrent Grade 4 adverse reaction Permanently discontinue COTELLIC.
Hide